Verition Fund Management
NKTR icon

Verition Fund Management’s Nektar Therapeutics NKTR Stock Holding History

Verition Fund Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,035
Closed -$297K – 3129
2025
Q4 		$297K Sell
7,035
-17,380
-71% -$973K ﹤0.01% 3003
2025
Q3 		$1.39M Buy
+24,415
New +$808K 0.01% 2283
2023
Q4 		– Sell
-116,238
Closed -$1.04M – 2571
2023
Q3 		$1.04M Buy
116,238
+110,238
+1,837% +$1.06M 0.01% 1058
2023
Q2 		$51.8K Buy
+6,000
New +$64K ﹤0.01% 2037
2022
Q4 		– Sell
-783
Closed -$38K – 2544
2022
Q3 		$38K Hold
783
– – ﹤0.01% 2718
2022
Q2 		$45K Buy
783
+101
+15% +$6.37K ﹤0.01% 2159
2022
Q1 		$55K Buy
+682
New +$101K ﹤0.01% 2481
2020
Q1 		– Sell
-1,295
Closed -$419K – 912
2019
Q4 		$419K Buy
+1,295
New +$376K 0.01% 732
2019
Q3 		– Sell
-477
Closed -$254K – 1234
2019
Q2 		$254K Buy
+477
New +$239K 0.01% 906
2018
Q4 		– Sell
-303
Closed -$277K – 1112
2018
Q3 		$277K Buy
+303
New +$259K 0.01% 1058
2018
Q2 		– Sell
-1,298
Closed -$2.07M – 1247
2018
Q1 		$2.07M Buy
+1,298
New +$1.67M 0.15% 138

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Verition Fund Management's NKTR Position: Q1 2026 in Review

Verition Fund Management sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 7,035 shares — an estimated $297K sold.

Verition Fund Management first reported a position in NKTR in Q1 2018 and held it in 11 quarters. The position peaked at $2.07M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Verition Fund Management reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 7,035 Nektar Therapeutics shares in Q1 2026, an estimated $297K.
  • Verition Fund Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 11 quarters.
  • Verition Fund Management's Nektar Therapeutics position peaked at $2.07M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.